Telix Pharmaceuticals Ltd has released a press release.
TLX250-CDx Indication Expansion - Preliminary Data
Filed with ASX ·
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Telix Pharmaceuticals
- Expansion of partnership with GE Healthcare in PET imaging
- Health Canada Approves Illuccix for Prostate Cancer Imaging
- Chinese NMPA Approves TLX250 Phase III registration study
- Telix Withdraws Marketing Application for Illuccix in Europe
- Final IPAX-1 Study Data Confirms Safety Tolerability Profile
Later from Telix Pharmaceuticals
- Appendix 4C and Activities Report - September 2022 Quarter
- Q3 2022 Business Update to accompany quarterly results
- ZIRCON Ph III Imaging Study - Positive Top-Line Results
- ZIRCON Ph III Imaging Study - Top-Line data presentation
- Telix Acquires Optimal Tracers
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals